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Cerebrospinal fluid (CSF) overproduction results from ei-
ther CSF infection or choroid plexus hypertrophy or tu-
mor, with only a single idiopathic case described so far. 
We report a unique case of a male infant with Crouzon 
syndrome who presented with intracranial hypertension, 
caused by up to 4-fold increase in CSF daily production. 
Conditions related to CSF overproduction, namely central 
nervous system infections and choroid plexus hypertrophy 
or tumor, were ruled out by repeated magnetic resonance 
imaging and CSF samples. Medical therapy failed to reduce 
CSF production and the patient underwent several shunt-
ing procedures, cranial expansion, and endoscopic coagu-
lation of the choroid plexus. This article thoroughly reviews 
pertinent literature on CSF production mechanisms and 
possible therapeutic implications.
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Hydrocephalus is generally defined as abnormal accumu-
lation of cerebrospinal fluid (CSF) within the ventricles and 
subarachnoid spaces, and is often associated with dilata-
tion of the ventricular system and increased intracranial 
pressure (ICP). It can be regarded as a disparity between 
production and absorption of cerebrospinal fluid (CSF), al-
most always as a result of CSF flow obstruction either at the 
ventricular level (eg, foramen of Monro, aqueduct of Syl-
vius, outlets of fourth ventricle) or the subarachnoid level 
(eg, basal cisterns, arachnoid granulations, or other points 
of absorption). More rarely hydrocephalus is a result of im-
paired absorption of CSF, due to increased venous pres-
sure in the dural sinuses or at the jugular veins (1) and even 
more rarely of choroid plexus hyperplasia (2-4) or choroid 
plexus tumors (5-7). Furthermore, CSF production may be 
increased by CSF infections and meningitis (8), along with 
the concomitant decrease in CSF absorption. Hydroceph-
alus resulting from excessive production of CSF and not 
related to the conditions described above has been de-
scribed in the literature by a single case report in 1989 (9).
We present a unique case of idiopathic CSF overproduc-
tion and the specific difficulties arising from its manage-
ment. This case prompted us to review the literature focus-
ing on the molecular mechanisms of CSF production and 
the drugs regulating this process.
Case RePoRT
A 6-month-old male infant, born to non-consanguineous 
parents, presented with macrocrania, irritability, and mul-
tiple episodes of vomiting. He also had dysmorphic fea-
tures, in particular low-set ears, hypertelorism with exor-
bitism, mandibular prognatism with inverted bite, and 
broad and varus big toes. The clinical diagnosis of Crou-
zon syndrome was confirmed by a genetic test, show-
ing FGFR2 gene mutation. Head computed tomography 
(CT) scan showed a premature fusion of the squamosal 
and parieto-mastoid suture bilaterally with open sutures 
at the cranial vault (Figure 1). Brain magnetic resonance 
imaging (MRI) showed a moderate ventriculomegaly with 
wide pericephalic subarachnoid spaces and a small-sized 
posterior cranial fossa with low insertion of the tentori-
um without Chiari malformation or crowded appearance 
of the neural structures. Angio-MR sequences showed a 
normal venous pattern with a slight predominance of the 
right transverse sinus. Prolonged monitoring (48 hours) of 
the ICP via an intraparenchymal sensor showed patholog-
ically high values. Thus, a ventriculoperitoneal shunt (VPS) 
was placed, with prompt resolution of the preoperative 
symptoms. Intraoperative CSF samples showed no evi-
dence of infections.
Two months later, the patient started vomiting daily. Pedi-
atric work-up ruled out systemic issues. MRI did not show 
any VPS malfunction but showed craniocerebral dispropor-
FiGuRe 1. Patient picture at presentation (A). 3D reconstruc-
tion of computed tomography (CT) scan showed that the 
sutures of the cranial vault were widely open, while the 
squamosal suture, as well as parieto-mastoid suture, was fused 
bilaterally (arrows) (B).
FiGuRe 2. Brain magnetic resonance imaging (MRi) at 
presentation showed ventricular dilation without apparent 
obstruction of the cerebrospinal fluid circulation (B),(C). MRi 
performed two months later ruled out shunt malfunction, 
but disclosed a crowded posterior cranial fossa with Chiari i 
malformation (C),(D), arrow).
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tion, with crowded posterior cranial fossa and downward 
herniation of cerebellar tonsils (Figure 2). A posterior crani-
al expansion with decompression of the foramen magnum 
was performed. The postoperative period was complicat-
ed by CSF leak at the surgical wound, requiring exterior-
ization of the shunt. Unexpectedly, the average amount of 
drained CSF was 1200 mL/d. Patient did not present with 
any symptom and CT scan ruled out any complication of 
overdrainage. Repeated CSF samples ruled out any infec-
tion. No evidence of choroid plexus hypertrophy or tumor 
was present on MRI. The CSF production was not reduced 
by a trial of acetazolamide, but was increased to 1400 
mL/d. Additionally, Colton blood group analysis showed 
a normal expression of Colton antigen, which is found on 
aquaporin 1 protein.
The subsequent placement of VPS was early complicated 
by massive ascites. Thus, we placed a ventriculoatrial shunt 
(VAS) and a concomitant “protective” external ventricular 
drainage (EVD). Transient closure of EVD, in order to chal-
lenge the cardio-vascular system to receive such a daily 
amount of CSF, was associated to an increased blood level 
of brain natriuretic peptide (BNP). Finally, two CSF shunt 
devices were concomitantly placed, namely a VPS on the 
left side and a VAS on the right side, both utilizing a middle 
pressure valve.
A few months later, the child suffered again from symp-
toms of increased intracranial pressure. After surgical revi-
sion of both shunting devices, MRI confirmed craniocer-
ebral disproportion with slit ventricles. A biparietal cranial 
expansion was therefore performed. However, postopera-
tive CSF drainage still ranged between 1400 mL and 1700 
mL per day, requiring once again dual shunting. After 5 
weeks a new shunt malfunction required exteriorization of 
both CSF shunts, confirming daily overproduction of CSF 
(about 1500 mL/d). A pharmacological approach with ter-
lipressin administration was attempted with poor results. 
Thus, in spite of normal appearance of the choroid plexus-
es at MRI, endoscopic choroid plexus coagulation was per-
formed bilaterally. Due to small ventricular size, the proce-
dure was performed through bilateral occipital access and 
using neuronavigation (Figure 3). Since the first post-oper-
ative day, the CSF drainage rate halved to 700-800 mL/d. 
In spite of this important reduction of the CSF production 
rate, it was necessary to perform dual shunting. The post-
operative course was uneventful and the patient was do-
ing well at 6-month follow-up.
DisCussion
Hydrocephalus resulting from CSF overproduction is a rare 
disease and is usually caused by pathological conditions 
affecting the choroid plexus, namely hyperplasia or tumor. 
In the last decade, endoscopic coagulation of the choroid 
plexus has become a treatment option for this condition, 
warranting shunt independency, with lower complication 
rate compared to surgical plexectomy (10). In the case of 
choroid plexus tumor, the surgical resection of the tumor 
usually reduces CSF production. Persistent hydrocephalus, 
requiring the placement of a CSF shunting device, is possi-
bly related to the concomitant impaired absorption of CSF, 
ascribed to chemical arachnoiditis secondary to the pres-
ence of the tumor in the ventricular system (11,12). Sim-
ilarly, CSF infections and meningitis (8) may increase the 
CSF production, along with the concomitant decrease in 
CSF absorption. Antibiotic treatment of the infection usu-
ally leads to normalization of CSF production but not nec-
essarily to the treatment of the associated hydrocephalus, 
since the structures devoted to the CSF absorption may 
be definitely impaired, thus usually requiring a shunt-
ing procedure.
FiGuRe 3. Brain magnetic resonance imaging (MRi) after 
Gadolinium administration ruled out pathological conditions 
affecting the choroid plexuses (A),(B). endoscopic pictures of 
the choroid plexus before (C) and during (D) the coagulation 
performed using the Thulium laser.
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To our knowledge, a single case of idiopathic CSF overpro-
duction, ie, not related to the conditions described above, 
has been reported in the English-language literature so far 
(9). In this case from 1989, increased daily production of 
CSF could have been exacerbated by the infections that 
the patient had suffered from in the months before the re-
ported CSF output records. Thus, hydrocephalus related 
to idiopathic CSF overproduction remains a questionable 
pathological entity.
In our case, there was no evidence of CSF infection in the 
patient’s clinical history. The patient with Crouzon syn-
drome suffered from a communicating hydrocephalus 
secondary to impressive idiopathic CSF overproduction. In 
patients with Crouzon syndrome, hydrocephalus is present 
in up to 40% of cases and is usually related to venous out-
let occlusion and small posterior cranial fossa (13). In the 
present case, the initial MRI showed normal dural sinuses 
anatomy, and the posterior cranial fossa was not particular-
ly small and crowded. Serial MRI performed to investigate 
the cause of CSF overproduction ruled out concomitant 
pathological conditions affecting the choroid plexuses. 
Interestingly, the patient did well over two months after 
the initial placement of a CSF shunt, so that it is possible 
that the device placement precipitated CSF overproduc-
tion via an unknown mechanism. The absence of underly-
ing conditions causing the CSF overproduction together 
with the young age of the patient and his comorbidities 
raised particular issues in the management of this case. 
The placement of VPS was complicated by massive ascites, 
as expected. Although in the previous case report, the 2.5-
year-old child with more than four times the expected rate 
of CSF production was successfully treated with a VAS (9), 
in the present case the cardiovascular system did not tol-
erate such a daily amount of CSF, so that we finally placed 
a VAS on the right side and a VPS on the left side. Cardi-
ac function was thereafter monitored by ultrasound and 
weekly blood level of BNP in order to promptly rule out any 
volume overload. Unfortunately, the presence of two CSF 
shunt devices reinforced the spontaneous tendency of 
the cranial vault sutures to fuse due to the underlying syn-
drome condition, thereby leading to the development of 
secondary craniosynostosis and craniocerebral dispropor-
tion (14). In spite of surgical expansion of the cranial vault, 
the ventricles remained particularly small, thus resulting in 
a constant risk of shunt obstruction.
Finally, the endoscopic coagulation of the choroid plexus, 
though initially contraindicated due to the risk related 
to the small size of the ventricular cavities, was per-
formed as a last resort option when the other treatment 
options failed. This procedure resulted in a significant re-
duction of CSF production, thus confirming its role in com-
plicated cases of hydrocephalus (15).
This unique case of idiopathic CSF overproduction prompt-
ed us to review the mechanisms of CSF production, which 
are still far from being completely understood, in order to 
identify possible targets of a medical therapy.
CsF production
CSF production is an active process, which according to 
the classical theory takes place mainly in the epithelial cells 
of the choroid plexuses (16-19). The driving force for flu-
id secretion is an osmotic gradient due to the active and 
unidirectional flux of ions from one side of the epithelial 
monolayer to the other (20). The main ions and small mol-
ecules secreted by the choroid plexus through transport-
ers and ion channels are Na+, Cl-, HCO3
- and H20, while K
+ 
ions are absorbed (21,22) (Table 1).
Moreover, there is active water secretion through trans-
membrane proteins referred to as aquaporins (AQPs) (39). 
Among the 13 known mammalian AQPs, five have been 
identified in the central nervous system (CNS), namely 
AQP1, AQP4, AQP7, AQP9, and AQP11 (40).
Although the mechanism of ion secretion has been clari-
fied and most of the involved transporters have now been 
localized to specific membranes (21,22), the role of AQPs 
in CSF physiology and pathophysiology is still uncertain. 
AQP 1 and 4 are the most expressed subtypes in the mam-
malian CNS. AQP1 is highly expressed at the apical sur-
face of the choroid plexus epithelium (39,41) whereas 
AQP4, the most abundant water channel in the brain, is 
expressed by ependymal cells, glia limitans interna and 
externa cells, at the perivascular end feet of astrocytes 
that form the blood-brain barrier, and in the cerebellum, 
supraoptic and suprachiasmatic nucleus of the hypothal-
amus, hippocampal dentate gyrus and areas CA-1 and 
CA-3, neocortex, nucleus of stria terminalis, and medial 
habenular nucleus (40).
Distribution of AQP1 at the choroid plexus apical sur-
face suggests its role in CSF production. Studies on AQP1 
knockout mice showed a decrease in both CSF produc-
tion and ICP values compared with wild-type mice, al-
though the latter effect could be related to the decrease 
in the central venous pressure in AQP1 knockouts due to 
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the effect on the kidneys (42,43). A recent literature search 
for articles on the role of AQP1 in hydrocephalus found 
just 5 papers, 3 on animal models and 2 on humans (44). 
Down-regulation of AQP1 has been reported in animal 
studies and in a case report on a 15-month-old girl with 
choroid plexus hyperplasia (45), while a small case series 
of choroid plexus tumors showed a heterogeneous pat-
tern of AQP1 in papillomas and a weak expression in a 
single case of choroid plexus carcinoma (46). These data 
suggest a possible existence of a feedback mechanism 
on AQP1 expression in response to hydrocephalus (40). In 
our case, chemical analysis of the CSF showed a normal 
glucose level, very low protein values (3-5 mg/dL), and 
absent cells in the patient’s clinical history. These data are 
consistent with active secretion of water at the ventricu-
lar level in spite of very low oncotic pressure of the CSF. 
Thus, even if no clinical case of hydrocephalus has been 
related to a pure deficiency of aquaporins, we performed 
a molecular analysis of Colton antigen expression during 
blood tests (Colton antigen is found on AQP1), in order to 
investigate any mutation of AQP1. However, this test did 
not show significant anomalies.
Studies on AQP4 role in brain edema in knockout mice 
models showed a protective role of the protein in va-
sogenic edema development but an active role in cyto-
toxic edema development (47,48). Animal hydrocephalus 
models showed an up-regulation of AQP4 expression in 
the blood-CSF and blood-brain barriers, suggesting the 
presence of an adaptive feedback mechanism that lowers 
the production and increases the clearance of CSF in cases 
when trans-parenchymal flow and hydrocephalic edema 
are observed (40). Recently, an increase in AQP4 has been 
reported in the CSF in human congenital hydrocephalus, 
which could be the result of ependyma denudation and 
subsequent diffusion of AQP4 from the parenchyma to 
the CSF (49). Recent data has focused on the role of AQP4, 
which is mainly distributed in the perivascular spaces, in 
the regulation of CSF homeostasis (50). Moreover, AQP4 
deficit has been shown to cause hydrocephalus in experi-
mental models (50).
In conclusion, the traditional explanation that the CSF 
is produced by the choroid plexuses and reabsorbed by 
the arachnoid villi has been questioned. A study in chil-
dren hypothesized the presence of a minor pathway in-
volving the perivascular spaces as a site of CSF reabsorp-
tion (51). The present case of persistent overproduction 
of CSF after the coagulation of the choroid plexuses fur-
ther brings into question the origin of the CSF. Recent 
insights have shifted the attention to the microvessels 
and their perivascular spaces, as sites responsible of 
TaBle 1. Main ion transporters and channels expressed in mammalian choroid plexus (CP)
Transporter Route of action site of expression in CP cells References
Na+-K+ATPase Na+ secretion
K+ absorption
Apical membrane (3 isoforms) Zlokovic et al 1993 (23)
Na+-K+ -2Cl- 
cotransporter
Still debated, probably absorption of Na+, Cl- and K+ Apical membrane Wu et al 1998 (24),
Angelow et al 2003 (25)
K+-Cl- 
cotransporters
K+ and Cl- secretion KCC3 isoform: Basolateral membrane
KCC4 isoform: Apical membrane





Basolateral membrane Johanson et al 1990 (27)
Na+- HCO3- 
cotransporters
Isoforms NBCn1 and NBCE: Na+ and HCO3-  absorption
Isoform NBC4g: HCO3-  secretion
NBCn1 and NBCE: Basolateral mem-
brane
NBC4g: Apical membrane
Praetorius et al 2004 (28);
Fukuda et al 2013 (29)
AQP1 Probably H2O secretion
Cation channel: Cs+, Na+, K+, and, to a lesser extent, TEA+ 
absorption
Apical membrane Nielsen et al 1993 (30);
Boassa et al 2006 (31)
AQP4 To be determined Cytoplasmatic organelles membranes Venero et al 1999 (32)
Kv channels K+ secretion Apical membrane (3 isoforms) Speake et al 2004 (33)
Kir channels K+ secretion Apical membrane Döring et al 1998 (34);
Nakamura et al 1999 (35)
Anion channelsInward-rectifying channels and volume-conductance 
channels: probably HCO3- and Cl-  secretion
Not known
(theoretical site: Apical membrane)
Speake et al 2000 (36)
TRP channels TRPV4 and TRPM3: non-selective cation channels that 
increase transcellular ion flux and paracellular perme-
ability to adjust to changes in extracellular osmolarity
Not known Liedtke et al 2000 (37);
Jo et al 2013 (38)
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the establishment of homeostasis between CSF and the 
interstitial fluid, questioning the net CSF production by 
the choroid plexus (52,53).
Regulation of CsF production
Different molecules have been implicated in the regula-
tion of CSF production (Table 2). One of the corticosteroid 
action mechanisms for reducing brain edema and ICP is 
the reduction of CSF production mediated by a decreased 
activity of Na+-K+ATPase (54).
Similarly, CSF production may be influenced by anesthetic 
agents (55). Halothane decreases CSF production by act-
ing on the V1 receptor of vasopressin, with no net change 
in the blood flow to the choroid plexus (56). Other agents, 
such as thiopental, midazolam, and etomidate, may de-
crease CSF production by reducing both cerebral blood 
flow (CBF) and cerebral metabolic rate for oxygen when 
used in high doses (57). Although opioid anesthetics, in-
cluding fentanyl, can increase ICP (58-60) and are generally 
believed not to influence CSF production (61), high doses 
of fentanyl have been reported to reduce CSF production 
in dogs (62). As opposed to this, ketamine increases the 
CSF production secondary to an increase in CBF (63). Enflu-
rane, despite a reduced CBF, causes an increase in choroid 
plexus metabolism, resulting in an increased CSF produc-
tion (64). Moreover it increases the resistance to reabsorp-
tion of CSF, which together with increased CSF production, 
contributes to increasing ICP (56,65).
Interestingly, a widely used substance such as caffeine, in 
rats showed opposite effects on CSF production: acute 
caffeine treatment (oral intake) reduced CSF production, 
while a chronic intake resulted in ventriculomegaly, due 
to increased CSF production and potentially associated 
periventricular leukomalacia (66). Such an effect of caffeine 
is mediated by A1 adenosine receptor. The increased CSF 
production is the result of an increased activity of Na+-K+ 
ATPase at the choroid plexus level, which establishes a so-
dium gradient across the choroid epithelial cells, as well as 
of an elevated CBF (66).
These molecules are not used in neurosurgical practice to 
regulate the CSF production, but acetazolamide, a carbon-
ic anhydrase inhibitor, has been used for a long time to re-
duce CSF production in idiopathic intracranial hyperten-
sion. In vivo studies after administration of acetazolamide 
showed a 50% decrease in CSF production despite a 2-fold 
increase in blood flow to choroid plexus (67). Carbonic an-
hydrases are a group of enzymes that catalyze the produc-
tion of HCO3
- and H+ from H2O and CO2. Although carbonic 
anhydrases are not directly involved in ion transport, they 
are believed to have an important role in CSF secretion on 
the basis of the effects of their inhibitors (21). Unfortunate-
ly, acetazolamide is not always effective and its long-term 
use can be difficult to tolerate by both adults and children. 
In children, potential side effects are lethargy, poor feed-
ing, tachypnea, diarrhea, and electrolyte imbalances (hy-
perchloremic metabolic acidosis). Finally, a paradoxical 
increase in CSF production may be observed after aceta-
TaBle 2. Drugs that may influence CSF production at choroid plexus level and their proposed mechanism of action
Drug effect on CsF production Proposed mechanism of action
Corticosteroids Reduced Reduced Na+-K+ATPase activity
Acetazolamide Reduced Carbonic anhydrase inhibitor
Interactions with AQP1 and AQP4
Furosemide Reduced Weak carbonic anhydrase inhibitor
Bumetanide Reduced Blocks Na+-K+ -2Cl- cotransporter
Inhibitory effect on AQP1 and AQP4
Vasopressin Reduced Choroid plexus arterioles vasoconstriction
Halotane Reduced Interaction with vasopressin V1 receptor
Thiopental (high doses) Reduced Reduction of CBF and cerebral metabolic rate for oxygen
Midazolam (high doses) Reduced Reduction of CBF and cerebral metabolic rate for oxygen
Etomidate (high doses) Reduced Reduction of CBF and cerebral metabolic rate for oxygen
Fentanyl (high doses) Reduced Not determined
Caffeine Acute effect: Reduced
Chronic effect: Increased
A1 adenosine receptor mediated increased Na
+-K+ATPase activity + 
Increased CBF
Ketamine Increased Increase in cerebral blood flow
Enflurane Increased Increase in choroid plexus metabolism
*abbreviations: aQP – aquaporin; CBF – cerebral blood flow.
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zolamide administration because of increased levels of cir-
culating CO2 and subsequent vasodilatation and increased 
cerebral blood flow, as observed in the present case. An-
other drug that has a weak carbonic anhydrase inhibition 
activity is the widely used loop diuretic furosemide, which 
has also been shown to decrease CSF production (68). 
Similarly, bumetanide, another loop diuretic, blocks Na+-K+ 
-2Cl- cotransporter, thus showing a significant reduction 
(47%) in CSF production in animal models (69). Interest-
ingly, butamenide also showed an inhibitory effect on 
AQP1 and AQP4 (70). This finding led to the development 
of molecules based on bumetanide structure like arylsul-
phonamide AqB013 as an antagonist for AQP1 and AQP4 
(71). It is worth to note that acetazolamide is also part of 
arylsulphonamide family. Although its potential effects on 
AQPs are still debated (72), recent studies have shown an 
interaction with AQP1, both in vitro (73) and in vivo (74), 
and a possible reversible inhibition of AQP4 (75).
Experimental data showed that circulating antidiuret-
ic hormone (ADH), also known as vasopressin, markedly 
decreased CSF production in rabbits (76) and sheep (77). 
This effect is presumably related to choroid plexus arteri-
oles vasoconstriction mediated by vasopressin V1a receptor, 
which has been localized on the choroidal tissue by both 
autoradiography and mRNA analysis (78,79). On the con-
trary, vasopressin V1b receptors, which mainly mediate corti-
cotrophin secretion from the pituitary, are less expressed in 
choroid plexus tissue. However, an increment in V1bR mRNA 
was documented after salt-loading, suggesting a role in the 
regulation of brain water content and cerebral edema (80).
The role of endogenous vasopressin in CSF is still debat-
ed and is probably related to brain water regulation (80). It 
may arise from three sources: transport into the CSF from 
peripheral blood (81,82), central release from hypotha-
lamic neurons (83), and in situ synthesis and release into 
the CSF from epithelial cells of the choroid plexus (84-86). 
Vasopressin production by the choroid plexus is increased 
by beta-adrenergic agonists and vasointestinal peptide, 
which indicates that the process is under both endocrine 
and neuronal control (87). Therefore, vasopressin could 
have an autocrine and paracrine effect, playing a role in 
the chain of events that enables either hormonal or neu-
ronal influence on the control of CSF production (20). In 
the present case report, an off-label medical trial with low 
dosage intravenous terlipressin was started with the par-
ents’ consent. Terlipressin is an analogue of vasopressin, 
acting on three different receptors: vasopressin receptor 
V1a, vasopressin receptor V1b, and, less actively, on va-
sopressin receptor V2, which controls free water absorp-
tion in the renal medulla. Its current clinical use is in septic 
shock (88), hepatorenal syndrome (89), and esophageal va-
rices bleeding (90). In the present case, this medical ther-
apy had a promising effect of halving the daily amount of 
drained CSF since the third day of therapy and the child 
maintained a good clinical status without hemodynamic 
complications. However, due to the risks related to a pro-
longed vasoconstrictor therapy, terlipressin was stopped 
after 6 days with a new increase in the drained CSF volume 
to pre-therapy levels without chemical or microbiologi-
cal alterations. Since the administration modality and po-
tential risks of cardiovascular disease and fluid imbalance 
do not make terlipressin an ideal candidate for long-term 
therapy, further studies should identify most manageable 
and selective analogues of vasopressin.
ConClusions
CSF production is a complex and active process that in-
volves a huge number of transporters, with insufficiently 
understood regulatory mechanism, which makes the man-
agement of idiopathic CSF overproduction a complicated 
issue. This extremely rare pathological condition could be 
related to the malfunction of ions or water transporters at 
ependymal and choroid plexus level or to an imbalance in 
the CSF production regulatory mechanism. Drug therapy 
has so far failed to control the CSF production, so that sur-
gical and endoscopic options, in particular choroid plexus 
coagulation, should be considered. A better understanding 
of the molecular substrates of the CSF production could 
lead to the development of targeted drugs that could re-
duce CSF production and alleviate intracranial hyperten-
sion symptoms in hydrocephalic patients and potentially 
have a role in reducing brain edema related to ischemic 
and neoplastic lesions.
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